Trial Outcomes & Findings for Estimation of the ED95 of Intrathecal Hyperbaric Prilocaine 2% With Sufentanyl for Scheduled Cesarean Delivery (NCT NCT03036384)

NCT ID: NCT03036384

Last Updated: 2020-05-06

Results Overview

The nerve blockade will be considered as success when a bilateral T4 level will reach in 15 minutes after intrathecal injection without additional epidural injection needed within 45 minutes peri-operative ; no pain at the skin incision, no pain during 45 minutes after the skin incision

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

40 participants

Primary outcome timeframe

during surgery (average 1 hour)

Results posted on

2020-05-06

Participant Flow

All participants were recruited at CHU Saint-Pierre.

Possible doses of HB prilocaine range from 30 to 55mg, but actual administrated doses will be defined by CRM

Participant milestones

Participant milestones
Measure
Cohort 1
45mg HB prilocaine initial dose; 4 patients
Cohort 2
40mg HB prilocaine following CRM results; 4 patients
Cohort 3
40mg HB prilocaine following CRM results; 4 patients
Cohort 4
35mg HB prilocaine following CRM results; 4 patients
Cohort 5
50mg HB prilocaine following CRM results, 4 patients
Cohort 6
45mg HB prilocaine following CRM results, 4 patients
Cohort 7
45mg HB prilocaine following CRM results, 4 patients
Cohort 8
45mg HB prilocaine following CRM results, 4 patients
Cohort 9
40mg HB prilocaine following CRM results, 4 patients
Cohort 10
45mg HB prilocaine following CRM results, 4 patients
Overall Study
STARTED
4
4
4
4
4
4
4
4
4
4
Overall Study
COMPLETED
4
4
4
4
4
4
4
4
4
4
Overall Study
NOT COMPLETED
0
0
0
0
0
0
0
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Estimation of the ED95 of Intrathecal Hyperbaric Prilocaine 2% With Sufentanyl for Scheduled Cesarean Delivery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
35mg HB Prilocaine
n=4 Participants
40mg HB Prilocaine
n=12 Participants
45mg HB Prilocaine
n=20 Participants
50mg HB Prilocaine
n=4 Participants
Total
n=40 Participants
Total of all reporting groups
Age, Continuous
29 years
STANDARD_DEVIATION 8.76 • n=99 Participants
35.08 years
STANDARD_DEVIATION 5.11 • n=107 Participants
32.85 years
STANDARD_DEVIATION 4.93 • n=206 Participants
29.85 years
STANDARD_DEVIATION 5.94 • n=7 Participants
32.75 years
STANDARD_DEVIATION 5.69 • n=31 Participants
Sex/Gender, Customized
Female
4 Participants
n=99 Participants
12 Participants
n=107 Participants
20 Participants
n=206 Participants
4 Participants
n=7 Participants
40 Participants
n=31 Participants
Sex/Gender, Customized
Male
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
0 Participants
n=31 Participants
Length
159.5 cm
STANDARD_DEVIATION 4.93 • n=99 Participants
164.42 cm
STANDARD_DEVIATION 4.45 • n=107 Participants
162.8 cm
STANDARD_DEVIATION 6.26 • n=206 Participants
157 cm
STANDARD_DEVIATION 6.16 • n=7 Participants
162.38 cm
STANDARD_DEVIATION 5.89 • n=31 Participants
Weight
73 kg
STANDARD_DEVIATION 16.02 • n=99 Participants
82.17 kg
STANDARD_DEVIATION 11.93 • n=107 Participants
79.78 kg
STANDARD_DEVIATION 11.6 • n=206 Participants
84.68 kg
STANDARD_DEVIATION 2.88 • n=7 Participants
80.31 kg
STANDARD_DEVIATION 11.62 • n=31 Participants
Gravity
3 number of pregnancies
STANDARD_DEVIATION 1.41 • n=99 Participants
2.17 number of pregnancies
STANDARD_DEVIATION 1.03 • n=107 Participants
3.1 number of pregnancies
STANDARD_DEVIATION 1.98 • n=206 Participants
2 number of pregnancies
STANDARD_DEVIATION 0.96 • n=7 Participants
2.70 number of pregnancies
STANDARD_DEVIATION 1.47 • n=31 Participants
Parity
1.25 number of deliveries
STANDARD_DEVIATION 0.5 • n=99 Participants
0.67 number of deliveries
STANDARD_DEVIATION 0.49 • n=107 Participants
1.3 number of deliveries
STANDARD_DEVIATION 1.98 • n=206 Participants
0.75 number of deliveries
STANDARD_DEVIATION 0.96 • n=7 Participants
1.05 number of deliveries
STANDARD_DEVIATION 1.47 • n=31 Participants
Previous Caesarean Section (CS)
no previous caeserean
2 Participants
n=99 Participants
7 Participants
n=107 Participants
10 Participants
n=206 Participants
3 Participants
n=7 Participants
22 Participants
n=31 Participants
Previous Caesarean Section (CS)
1 previous caeserean
2 Participants
n=99 Participants
5 Participants
n=107 Participants
10 Participants
n=206 Participants
1 Participants
n=7 Participants
18 Participants
n=31 Participants
Term
38.5 weeks
STANDARD_DEVIATION 0.58 • n=99 Participants
38.42 weeks
STANDARD_DEVIATION 1.08 • n=107 Participants
38.40 weeks
STANDARD_DEVIATION 0.94 • n=206 Participants
38.75 weeks
STANDARD_DEVIATION 1.26 • n=7 Participants
38.45 weeks
STANDARD_DEVIATION 0.96 • n=31 Participants

PRIMARY outcome

Timeframe: during surgery (average 1 hour)

The nerve blockade will be considered as success when a bilateral T4 level will reach in 15 minutes after intrathecal injection without additional epidural injection needed within 45 minutes peri-operative ; no pain at the skin incision, no pain during 45 minutes after the skin incision

Outcome measures

Outcome measures
Measure
Cohort 1
n=4 Participants
45mg
Cohort 2
n=4 Participants
40mg
Cohort 3
n=4 Participants
40mg
Cohort 4
n=4 Participants
35mg
Cohort 5
n=4 Participants
50mg
Cohort 6
n=4 Participants
45mg
Cohort 7
n=4 Participants
45mg
Cohort 8
n=4 Participants
45mg
Cohort 9
n=4 Participants
40mg
Cohort 10
n=4 Participants
45mg
Success of Anesthesia
Success
4 Participants
4 Participants
4 Participants
1 Participants
4 Participants
4 Participants
4 Participants
4 Participants
3 Participants
3 Participants
Success of Anesthesia
Failure
0 Participants
0 Participants
0 Participants
3 Participants
0 Participants
0 Participants
0 Participants
0 Participants
1 Participants
1 Participants

SECONDARY outcome

Timeframe: Until complete release of sensory block (T12-S1) (average 4 hours)

Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95

Level of Sensory block assessed as loss of sensation to cold, every 2 minutes after spinal anesthesia during 15 minutes, then every 5 minutes until the end of surgery, thereafter, once 30 minutes until total regression of sensory block (T12-S1).

Outcome measures

Outcome measures
Measure
Cohort 1
n=19 Participants
45mg
Cohort 2
n=4 Participants
40mg
Cohort 3
40mg
Cohort 4
35mg
Cohort 5
50mg
Cohort 6
45mg
Cohort 7
45mg
Cohort 8
45mg
Cohort 9
40mg
Cohort 10
45mg
Sensitive Block Duration
2.31 hours
Standard Deviation 0.48
3.25 hours
Standard Deviation 0.50

SECONDARY outcome

Timeframe: Until complete release of sensory block (T12-S1) (average 4 hours)

Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95

Level of Sensory block assessed as loss of sensation to cold, every 2 minutes after spinal anesthesia during 15 minutes, then every 5 minutes until the end of surgery, thereafter, once 30 minutes until total regression of sensory block (T12-S1). For this study, dermatome levels are depicted on a scale ranging from 1 to 18. (1 to 12 = T1-T12 thoracic levels; 13 to 17 = L1-L5 lumbar levels; 18 = S1 sacral level)

Outcome measures

Outcome measures
Measure
Cohort 1
n=19 Participants
45mg
Cohort 2
n=4 Participants
40mg
Cohort 3
40mg
Cohort 4
35mg
Cohort 5
50mg
Cohort 6
45mg
Cohort 7
45mg
Cohort 8
45mg
Cohort 9
40mg
Cohort 10
45mg
Sensitive Block at End of Surgery
3.88 Dermatome level
Standard Deviation 1.59
3.00 Dermatome level
Standard Deviation 0.82

SECONDARY outcome

Timeframe: Until complete release of motor block (Bromage scale = 1; average 4 hours)

Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95

Bromage scale (1 = no motor block; 2 = hip blocked; 3 = hip and knee blocked; and 4 = hip, knee, and ankle blocked) was used to evaluate the motor block every 15 minutes after spinal anaesthesia (T0) and until the end of surgery. Duration was defined from the time of the spinal injection until Bromage scale = 1.

Outcome measures

Outcome measures
Measure
Cohort 1
n=19 Participants
45mg
Cohort 2
n=4 Participants
40mg
Cohort 3
40mg
Cohort 4
35mg
Cohort 5
50mg
Cohort 6
45mg
Cohort 7
45mg
Cohort 8
45mg
Cohort 9
40mg
Cohort 10
45mg
Motor Block Duration
2.75 hours
Standard Deviation 0.45
3.50 hours
Standard Deviation 0.58

SECONDARY outcome

Timeframe: Until complete release of motor block (average 4 hours)

Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95

Bromage scale (1 = no motor block; 2 = hip blocked; 3 = hip and knee blocked; and 4 = hip, knee, and ankle blocked) was used to evaluate the motor block every 15 min after spinal anaesthesia (T0) and until the end of surgery.

Outcome measures

Outcome measures
Measure
Cohort 1
n=19 Participants
45mg
Cohort 2
n=4 Participants
40mg
Cohort 3
40mg
Cohort 4
35mg
Cohort 5
50mg
Cohort 6
45mg
Cohort 7
45mg
Cohort 8
45mg
Cohort 9
40mg
Cohort 10
45mg
Bromage Motor Block Level at End of Surgery
3.56 score on a scale
Standard Deviation 0.51
4.00 score on a scale
Standard Deviation 0.00

SECONDARY outcome

Timeframe: up to 10 minutes after baby extraction

Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95

Newborn Apgar score assessed at 1, 5, 10 minutes after baby extraction. The Apgar score is determined by evaluating the newborn baby on five simple criteria on a scale from 0 to 2, then summing up the five values thus obtained. The overall resulting score ranges from 0 to 10 ( 0-3 : severely depressed, 4-6 : Moderately depressed and 7-10 : Excellent condition). The five criteria are summarized using words chosen to form an abbreviation (Appearance, Pulse, Grimace, Activity, Respiration).

Outcome measures

Outcome measures
Measure
Cohort 1
n=19 Participants
45mg
Cohort 2
n=4 Participants
40mg
Cohort 3
40mg
Cohort 4
35mg
Cohort 5
50mg
Cohort 6
45mg
Cohort 7
45mg
Cohort 8
45mg
Cohort 9
40mg
Cohort 10
45mg
Newborn Apgar Score
Apgar at 1 minute
8.47 score on a scale
Standard Deviation 1.84
9.00 score on a scale
Standard Deviation 0.82
Newborn Apgar Score
Apgar at 5 minutes
9.63 score on a scale
Standard Deviation 0.96
9.75 score on a scale
Standard Deviation 0.50
Newborn Apgar Score
Apgar at 10 minutes
9.84 score on a scale
Standard Deviation 0.50
10 score on a scale
Standard Deviation 0

SECONDARY outcome

Timeframe: average 1 hour

Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95

Newborn Methemoglobinemia (MetHb) will be assessed at delivery by cordal blood sample, as a routine control, and expressed as a percentage of total hemoglobinemia.

Outcome measures

Outcome measures
Measure
Cohort 1
n=10 Participants
45mg
Cohort 2
n=1 Participants
40mg
Cohort 3
40mg
Cohort 4
35mg
Cohort 5
50mg
Cohort 6
45mg
Cohort 7
45mg
Cohort 8
45mg
Cohort 9
40mg
Cohort 10
45mg
Newborn Methemoglobinemia (MetHb)
1.59 percentage of MetHb
Standard Deviation 0.53
1.60 percentage of MetHb

SECONDARY outcome

Timeframe: during surgery (average 1 hour)

Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95

Arterial blood pressure will be measured at every 2.5 minute during surgery, then at every 20 minutes in the PACU (Post Anesthesia Care Unit). Vasopressors were given for patients with low blood pressure. A low blood pressure is defined as a blood pressure lower than 20% or more than the basal blood pressure (Systolic blood pressure before spinal anesthesia).

Outcome measures

Outcome measures
Measure
Cohort 1
n=19 Participants
45mg
Cohort 2
n=4 Participants
40mg
Cohort 3
40mg
Cohort 4
35mg
Cohort 5
50mg
Cohort 6
45mg
Cohort 7
45mg
Cohort 8
45mg
Cohort 9
40mg
Cohort 10
45mg
Number of Participants Needing Vasopressors
15 Participants
2 Participants

SECONDARY outcome

Timeframe: up to 5 Days

Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95

TNS are defined as pain and/or dysesthesia occurred after complete release of sensory block at the gluteal level, at the thighs and at the legs. At Day 0, Day 1, Day 3 and Day 5

Outcome measures

Outcome measures
Measure
Cohort 1
n=19 Participants
45mg
Cohort 2
n=4 Participants
40mg
Cohort 3
40mg
Cohort 4
35mg
Cohort 5
50mg
Cohort 6
45mg
Cohort 7
45mg
Cohort 8
45mg
Cohort 9
40mg
Cohort 10
45mg
Number of Participants With Transient Neurologic Symptoms (TNS)
0 Participants
0 Participants

SECONDARY outcome

Timeframe: up to 24 hours after surgery

Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95

from 15 minutes after spinal anesthesia and every 4 hours for 24 hours (score 0=no symptoms; 1=symptoms with no treatment necessary; 2=symptoms present and treated)

Outcome measures

Outcome measures
Measure
Cohort 1
n=19 Participants
45mg
Cohort 2
n=4 Participants
40mg
Cohort 3
40mg
Cohort 4
35mg
Cohort 5
50mg
Cohort 6
45mg
Cohort 7
45mg
Cohort 8
45mg
Cohort 9
40mg
Cohort 10
45mg
Number of Participants With Nausea or Vomiting
3 Participants
0 Participants

SECONDARY outcome

Timeframe: Up to 24 hours after surgery

Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95

from 15 minutes after spinal anesthesia and every 4 hours for 24 hours (score 0=no symptoms; 1=symptoms with no treatment necessary; 2=symptoms present and treated)

Outcome measures

Outcome measures
Measure
Cohort 1
n=19 Participants
45mg
Cohort 2
n=4 Participants
40mg
Cohort 3
40mg
Cohort 4
35mg
Cohort 5
50mg
Cohort 6
45mg
Cohort 7
45mg
Cohort 8
45mg
Cohort 9
40mg
Cohort 10
45mg
Number of Participants With Pruritus
0 Participants
0 Participants

SECONDARY outcome

Timeframe: Up to 24 hours after surgery

Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95

All parturients will be questioned for urinary retention (yes or no)

Outcome measures

Outcome measures
Measure
Cohort 1
n=19 Participants
45mg
Cohort 2
n=4 Participants
40mg
Cohort 3
40mg
Cohort 4
35mg
Cohort 5
50mg
Cohort 6
45mg
Cohort 7
45mg
Cohort 8
45mg
Cohort 9
40mg
Cohort 10
45mg
Number of Participants With Urinary Retention
0 Participants
0 Participants

SECONDARY outcome

Timeframe: Up to 24 hours after surgery

Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95

All parturients will be questioned for dizziness (yes or no)

Outcome measures

Outcome measures
Measure
Cohort 1
n=19 Participants
45mg
Cohort 2
n=4 Participants
40mg
Cohort 3
40mg
Cohort 4
35mg
Cohort 5
50mg
Cohort 6
45mg
Cohort 7
45mg
Cohort 8
45mg
Cohort 9
40mg
Cohort 10
45mg
Number of Participants With Dizziness
5 Participants
2 Participants

SECONDARY outcome

Timeframe: up to 1 hour after surgery

Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95

Maternal satisfaction (yes or no) will be assessed 1 hour after surgery in the PACU (Post Anesthesia Care Unit)

Outcome measures

Outcome measures
Measure
Cohort 1
n=19 Participants
45mg
Cohort 2
n=4 Participants
40mg
Cohort 3
40mg
Cohort 4
35mg
Cohort 5
50mg
Cohort 6
45mg
Cohort 7
45mg
Cohort 8
45mg
Cohort 9
40mg
Cohort 10
45mg
Number of Satisfied Participants
16 Participants
4 Participants

Adverse Events

35mg HB Prilocaine

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

40mg HB Prilocaine

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

45mg HB Prilocaine

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

50mg HB Prilocaine

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Panayota Kapessidou

Centre Hospitalier Universitaire Saint Pierre

Phone: +32.2.535

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place